Is valproate monotherapy a practical possibility in chronically uncontrolled epilepsy?

Area of Science:

• Neurology
• Clinical Pharmacology
• Epileptology

Background:

• Epilepsy management in institutionalized individuals with intellectual disabilities often involves polytherapy.
• Optimizing antiepileptic drug regimens is crucial for improving seizure control and minimizing adverse effects.

Purpose of the Study:

• To evaluate the efficacy and safety of transitioning from polytherapy to valproate monotherapy in institutionalized male epileptic patients.
• To assess the impact of carbamazepine addition or substitution on seizure control.
• To investigate the relationship between valproate serum levels and clinical outcomes.

Main Methods:

• Prospective open study involving 20 male residents of a mental handicap institution with epilepsy.
• Gradual reduction of polytherapy to valproate monotherapy in 18 subjects.
• Addition or substitution with carbamazepine for subjects with inadequate seizure control.
• Monitoring of seizure frequency, adverse effects, and serum drug levels.

Main Results:

• Valproate monotherapy was associated with a significant disadvantage in seizure frequency control.
• Addition or substitution with carbamazepine led to significant improvements in seizure control.
• Phenobarbitone and phenytoin were successfully phased out.
• No clear association was found between valproate serum levels and seizure control or toxicity, despite some instances of pancreatitis and thrombocytopenia.
• No tremor or weight gain was observed with valproate.

Conclusions:

• Valproate monotherapy is not appropriate for institutionalized patients with chronically uncontrolled seizures.
• Carbamazepine, alone or in combination with valproate, represents a more effective treatment strategy for this population.
• Discontinuation of phenobarbitone and phenytoin was achieved without apparent negative consequences.